January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.
37 citations
,
January 1986 in “Carcinogenesis” ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.
April 2024 in “DAHUDER Medical journal” Ocrelizumab may cause pancreatitis in some patients.
9 citations
,
May 2014 in “Clinical Cosmetic and Investigational Dermatology” Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
May 2024 in “Indian Journal of Pharmacology” Tofacitinib effectively regrew scalp hair in an 11-year-old girl with alopecia areata.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
18 citations
,
February 2023 in “PLoS ONE” A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.
81 citations
,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
1 citations
,
March 2021 in “Journal of Investigative Dermatology” Sirolimus can reduce tumor cell size in TSC-related skin tumors, but continuous treatment is needed to maintain benefits.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
1 citations
,
April 2004 in “Cancer” Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
65 citations
,
March 2004 in “Journal of Clinical Investigation” Inhibiting ornithine decarboxylase may help prevent certain skin cancers.
July 2026 in “Materials Today Bio” The MQ complex helps heal melanoma wounds by controlling ROS levels with light.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
1 citations
,
April 2024 in “Anais Brasileiros de Dermatologia”